Anti-CD94 Antibodies for Enhanced Immune Response to Cancer Cells

Technology Description

Current cancer therapies often have limitations such as off-target effects, development of resistance, and limited efficacy against certain cancer types. There is a pressing need for therapies that can specifically target cancer cells and enhance the body’s natural immune response against these malignant cells. The inventors have developed a novel therapeutic approach that uses anti-CD94 antibodies to deplete NK cells in a cancer patient. 

Application

This method enhances the targeting and killing of cancer cells by activated T cells, such as CD8+ effector T cells. The anti-CD94 antibodies can be administered in conjunction with other therapies like checkpoint inhibitors and antigen administration for cancer antigens. The antibodies can also be used to reduce an NK cell-mediated immune response to non-self cells or tissues transplanted in an individual, thereby enhancing the effectiveness of therapies such as CAR T-cell therapy.

Data Availability

The inventors have shown specific binding regions and potential for high affinity binding to CD94.

Patent Status

Additional Patents Pending